Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep-Oct;22(5):485-492.
doi: 10.4103/aja.aja_120_19.

Anti-lysyl oxidase combined with a vacuum device induces penile lengthening by remodeling the tunica albuginea

Affiliations

Anti-lysyl oxidase combined with a vacuum device induces penile lengthening by remodeling the tunica albuginea

Tao Li et al. Asian J Androl. 2020 Sep-Oct.

Abstract

This study aimed to explore whether and how anti-lysyl oxidase (anti-LOX) combined with a vacuum device (VD) could promote penile lengthening and to evaluate the effect on erectile function. This study was performed on four groups of adult rats: control, anti-LOX, VD (negative pressure value of -300 mmHg), and anti-LOX + VD. Penile length was measured by a modified VD method and verified on exposed length data. Intracavernous pressure (ICP) and maximum ICP/mean arterial pressure (MAP) ratio were recorded to assess erectile function. For corpus cavernosum, LOX activity and concentrations of pyridinoline, desmosine, hydroxyproline, and elastin were analyzed; transmission electron microscope and Hart's elastin staining were performed to monitor microstructural changes. Anti-LOX and VD significantly lengthened the penis by 10.8% (3.75 mm) and 8.2% (2.48 mm) compared with the control group, respectively, while anti-LOX + VD achieved the longest penile size (40.58 ± 0.40 mm) which was 17.4% longer than the control group (34.58 ± 0.54 mm). After 1-week washout, no penile retraction was observed. Meanwhile, exposed penile length data confirmed that the penis in the anti-LOX + VD group was also significantly longer. Anti-LOX inhibited LOX activity to reduce pyridinoline level, which led the penile tunica albuginea remodeling. However, it had no effect on hydroxyproline, desmosine, and elastin levels. Moreover, anti-LOX had no impact on erectile function, which was determined by ICP and ICP/MAP ratio. These results suggest that anti-LOX elongates the penis by reducing pyridinoline, which induces tunica albuginea remodeling. This lengthening effect was more obvious when combined with a VD. All procedures had no impact on erectile function.

Keywords: anti-lysyl oxidase; crosslinking; penile lengthening; tunica albuginea remodeling; vacuum device.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Anti-LOX combined with a VD induces penile lengthening (n = 6 per group). (a) Representative images of penile length. (b) Representative images of penile length after a 1-week washout period. For a and b, penile length was measured under unified vacuum device aspiration condition (measured at –200 mmHg for 5 min twice with a 2-min interval). (c) Exposed penile length; the length was measured from the junction of urethral bulb and corpus cavernosum (marked with yellow line), to tip of glans cartilage; the measurement errors of length data were corrected on recorded images. (d) Statistical analysis of penile length (P < 0.0001). (e) Statistical analysis of penile length after a 1-week washout period (P < 0.0001). (f) Statistical analysis for exposed penile length (P < 0.0001). Anti-LOX: intragastric administration of β-aminopropionitrile (BAPN) with a dose of 100 mg kg−1 day−1; VD: vacuum device aspiration with negative pressure of -300 mmHg. **P < 0.01, ***P < 0.0001. LOX: lysyl oxidase.
Figure 2
Figure 2
LOX variation in corpus cavernosum in rats with 8, 12, 16, 24, and 48 weeks, respectively (n = 6 per group). (a) Representative image from Western blot. (b) Statistical analysis revealed that LOX expression was the highest at 8 weeks of age, which was significantly decreased with age (P < 0.0001). (c) LOX activity was the highest at 8 weeks of age; it was then significantly declined (P < 0.0001) and finally attained a relative stable level (P > 0.05). *P < 0.05, ***P < 0.0001. LOX: lysyl oxidase; RFUs: relative fluorescent units.
Figure 3
Figure 3
Anti-LOX combined with a VD does not impact normal erectile function (n = 6 per group). (a) Representative images of ICP under cavernous nerve stimulation. (b) Representative images of arterial pressure under cavernous nerve stimulation. (c) Statistical analysis of ICP (P = 0.4512). (d) Statistical analysis of mean arterial pressure (MAP; P = 0.1017). (e) Statistical analysis of ICP/MAP ratio (P = 0.4297). Anti-LOX: intragastric administration of β-aminopropionitrile (BAPN) with a dose of 100 mg kg−1 day−1; VD: vacuum device aspiration with negative pressure of -300 mmHg. LOX: lysyl oxidase; ICP: intracavernous pressure.
Figure 4
Figure 4
Biomarker analysis for corpus cavernosum. (a) anti-LOX and anti-LOX + VD groups exhibited significantly lower lysyl oxidase (LOX) activity than control and VD groups, respectively (P = 0.0149). (b) No significant difference was found on HYP (P = 0.5440) level. (c) No significant difference was found on total elastin content (P = 0.2228). (d) Anti-LOX group showed significantly lower PYD concentration than the control group (P = 0.0449), while anti-LOX + VD revealed significant lower level than the control (P = 0.0015) and −300 mmHg (P = 0.0015) groups. (e) No significant difference was found on DES concentration (P = 0.8226). n = 6 per group. Anti-LOX: intragastric administration of β-aminopropionitrile (BAPN) with a dose of 100 mg kg−1 day−1. VD: vacuum device aspiration with negative pressure of -300 mmHg. *P < 0.05, ***P < 0.0001. RFUs: relative fluorescent units; LOX: lysyl oxidase; HYP: hydroxyproline; PYD: pyridinoline; DES: desmosines.
Figure 5
Figure 5
Transmission electron microscopy in tunica albuginea of corpus cavernosum (n = 2 per group). (a) In longitudinal section, anti-LOX + VD group showed loosely arranged collagen fibers (scale bars = 1 μm). (b) In cross section, remodeled appearances of collagen bundlea were more obvious in anti-LOX, VD, and anti-LOX + VD groups, they also showed irregular arranged collagen bundles and less ground substance, compared with the control group (scale bars = 2 μm). Anti-LOX: intragastric administration of β-aminopropionitrile (BAPN) with a dose of 100 mg kg−1 day−1. VD: vacuum device aspiration with negative pressure of -300 mmHg. LOX: lysyl oxidase.
Figure 6
Figure 6
Hart's elastin staining in rat models (n = 6 per group). (a) Tunica albuginea showed blue-black to blue elastic fibers, which was abundant between Buck's fascia and tunica (at ×50 magnification, scale bars = 200 μm), representative elastic fibers on the upper left box (at ×400 magnification, scale bars = 50 μm); elastic fibers with regular shapes were tightly intertwined with collagen bundles along tunica albuginea. (b) Representative elastic fibers of corpus spongiosum at ×100 magnification (scale bars = 100 μm). Corpus spongiosum revealed substantially abundant elastic fibers with a tortuous appearance. (c) Elastic fibers of corpus spongiosum at 0 o'clock (at ×200 magnification, scale bars = 100 μm). (d) Cumulative area of elastic fibers in corpus spongiosum (0, 3, 6, and 9 o'clock at ×200 magnification), with insignificant difference found (P = 0.1865). Anti-LOX: intragastric administration of β-aminopropionitrile (BAPN) with a dose of 100 mg kg−1 day−1; VD: vacuum device aspiration with negative pressure of -300 mmHg. LOX: lysyl oxidase.

Similar articles

Cited by

References

    1. Ghanem H, Glina S, Assalian P, Buvat J. Position paper: management of men complaining of a small penis despite an actually normal size. J Sex Med. 2013;10:294–303. - PubMed
    1. Tomova A, Deepinder F, Robeva R, Lalabonova H, Kumanov P, et al. Growth and development of male external genitalia: a cross-sectional study of 6200 males aged 0 to 19 years. Arch Pediatr Adolesc Med. 2010;164:1152–7. - PubMed
    1. Vardi Y. Is penile enlargement an ethical procedure for patients with a normal-sized penis? Eur Urol. 2006;49:609–11. - PubMed
    1. Nugteren HM, Balkema GT, Pascal AL, Schultz WC, Nijman JM, et al. Penile enlargement: from medication to surgery. J Sex Marital Ther. 2010;36:118–23. - PubMed
    1. Colombo F, Casarico A. Penile enlargement. Curr Opin Urol. 2008;18:583–8. - PubMed

Publication types

MeSH terms